Cognetivity Neurosciences Trades on the OTCQB

VANCOUVER, Sept. 4, 2018 /CNW/ - Cognetivity Neurosciences Ltd. (the "Company" or "Cognetivity") (CSE: CGN) (FWB: 1UB) is pleased to announce that it is now trading on the OTCQB in the United States of America.  Cognetivity is now trading under the symbol CGNSF. The Company will also continue trading on the Canadian Securities Exchange ("CSE").

The Company's CEO and Director, Sina Habibi, commented, "As part of our strategy to continue to increase value for our shareholders we are very happy to announce that we have listed on the OTCQB market in the USA under the ticker symbol CGNSF. This is an important step in our public market strategy and will allow US investors an easier route to getting involved in the Cognetivity story. We have a growing exposure to the US market with our attendance at recent conferences and we will be taking the opportunity to grow our investor network in the largest capital markets going forwards. The USA forms an important part of our mission to help as many people as possible through our early diagnosis platform and we look forward to continuing to grow our presence there."

About Cognetivity Neurosciences Ltd.

Cognetivity is a technology company developing a cognitive testing platform, the Integrated Cognitive Assessment (ICA) for use in medical and commercial environments. Cognetivity's ICA uses Artificial Intelligence and machine learning techniques to help detect the earliest signs of impairment by testing the performance of large areas of the brain, potentially allowing early diagnosis of dementia. Cognetivity aims to develop the ICA through planned clinical studies to the market in North America and Europe.

For more information please visit – www.cognetivity.com

ON BEHALF OF THE BOARD

 "Sina Habibi"                                               

Sina Habibi

Chief Executive Officer and Director

FORWARD LOOKING STATEMENTS:

The forward-looking information contained in this press release is made as of the date of this press release and, except as required by applicable law, the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking information, whether as a result of new information, future events or otherwise, except as may be required by law. By its very nature, such forward-looking information requires the Company to make assumptions that may not materialize or that may not be accurate. This forward-looking information is subject to known and unknown risks and uncertainties and other factors, which may cause actual results, levels of activity and achievements to differ materially from those expressed or implied by such information.

The Exchange does not accept responsibility for the adequacy or accuracy of this release

SOURCE Cognetivity Neurosciences Ltd

Email: [email protected]; For media enquiries contact: Josh Stanbury, Email: [email protected]